HOME >> MEDICINE >> NEWS
Infliximab could offer long-term benefits to people with Crohns disease

Sustained use of the drug infliximab could offer substantial clinical benefit to people with Crohns disease, conclude authors of a study in this weeks issue of THE LANCET.

Crohns disease is a chronic inflammatory disorder of the intestines. Patients often have to be treated with steroids, which are associated with severe side-effects. Previous research has suggested that the drug infliximab could reduce disease symptoms in the short term; Stephen Hanauer and colleagues from the University of Chicago, USA, investigated whether treatment with infliximab every two months could be more effective in reducing the symptoms of Crohns disease in the longer term compared with a single infusion of the drug.

355 patients with severe Crohns disease from the USA, Europe, and Israel who responded within two weeks to an initial 5 mg/kg intravenous infusion of infliximab took part in the study. They were randomly assigned repeat infusions of placebo, repeat infusions of 5 mg/kg infliximab, or 10 mg/kg infliximab (after two treatments with 5mg/kg infliximab). Treatment took place at randomisation, after one month, and thereafter every two months for a year.

More than twice as many people given infliximab every two months were in remission after 30 weeks compared with patients who only received initial infliximab treatment followed by placebo. Patients given sustained infliximab responded for longer (for 38 and 54 weeks for 5mg/kg and 10mg/kg regimens, respectively) compared with patients given placebo (who only responded to treatment for an average of 19 weeks). Patients given infliximab were also more likely to discontinue use of steroids compared with those given placebo.

Stephen Hanauer comments: This study was important to demonstrate a sustained response to maintenance treatment with infliximab in Crohns disease, similar to the results with maintenance treatment for rheumatoid arthritis. After a series of inductive infusions at baseline, 2 and
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
2-May-2002


Page: 1 2

Related medicine news :

1. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
2. Novel therapy tested in mice could chase away cat allergies
3. Costs of antidepressants could have funded effective alternatives
4. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
5. Blood pressure treatment could cut risk of strokes and heart attacks
6. Proteins found in urine of pregnant women could help diagnose preeclampsia
7. Three out of the four million newborn babies who die each year could be saved
8. Increasing physician volume requirement could improve mammogram accuracy, study concludes
9. Chemicals in apples could reduce the risk of breast cancer, Cornell study in rats suggests
10. Training could remove racial bias from police reactions
11. Test could improve detection of prion disease in humans

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & ... **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... (CA) and preventive action (PA)? , The methods share techniques and tools but ...
(Date:2/17/2017)... ... , ... Program will serve more than 5,000 kids in ... Foundation announced today that they have awarded nine grants to expand the Foundation’s ... mentoring program, teaches kids the fundamentals of soccer while striving to help them ...
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a national ... was named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. ... made notable contributions to the staffing industry over the last twelve months. Industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists ... from February 21 - 23 in Beaver Creek, CO. It was announced today by ... second year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati knows ... of research, development and clinical trials, the founder of Chigurupati Technologies has invented ... of FDA approved ingredients that when infused into alcohol, protect the consumer’s liver ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... CINCINNATI , Feb. 17, 2017  Ethicon, ... Torax Medical, Inc., a privately held medical device ... Reflux Management System, a novel minimally invasive ... acquisition of Torax Medical will enable Ethicon to ... the anatomy-altering laparoscopic Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... AMSTERDAM , Feb. 17, ... connected health offerings at the  ...  (NYSE: PHG,AEX: PHIA), a global ... a broad range of population ... personal health solutions, fully integrated in a ...
Breaking Medicine Technology:
Cached News: